Publications by authors named "Fahim Malik"
Article Synopsis
- Chronic antibody-mediated rejection (CAMR) is a significant cause of kidney transplant failure, often resistant to standard immunosuppressive therapies like prednisone and mycophenolate mofetil.
- In a study of 31 patients with CAMR, those treated with the drug Rituximab had a longer median survival time for their kidney transplants (685 days) compared to those who did not receive the treatment (439 days).
- While Rituximab showed therapeutic benefits, the positive effects were only observed in a specific subgroup of patients, highlighting the need for further research to identify which patients might benefit most.
Autoantibodies to the M-type phospholipase A(2) receptor (PLA(2)R) are sensitive and specific for idiopathic membranous nephropathy. The anti-B cell agent rituximab is a promising therapy for this disease, but biomarkers of early response to treatment currently do not exist. Here, we investigated whether levels of anti-PLA(2)R correlate with the immunological activity of membranous nephropathy, potentially exhibiting a more rapid response to treatment than clinical parameters such as proteinuria.
View Article and Find Full Text PDF